Cor Vasa 2010, 52(3):183-186 | DOI: 10.33678/cor.2010.046

The effects of losartan on central and peripheral blood pressure

Jiří Widimský jr.*, Ondřej Petrák, Branislav Štrauch, Alice Vranková, Tomáš Zelinka, Jana Dvořáková, Robert Holaj
Centrum pro hypertenzi, III. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

We evaluated the antihypertensive effects of 100 mg losartan administered once daily for six months in patients with mild essential hypertension. The antihypertensive effects were assessed by measuring office and 24-hour blood pressure (BP), the latter using ambulatory blood pressure monitoring (ABPM). Additionally, central BP and aortic stiffness were measured by means of a Sfygmocor device.
Losartan treatment resulted in a significant decrease in office systolic and diastolic BP (134 ± 15 vs. 143 ± 13 mmHg; p < 0.05 and 78 ± 6 vs. 82 ± 8 mmHg; p < 0.04). Ambulatory BP monitoring demonstrated a marked losartan-induced decrease in 24-hour systolic and diastolic BP (126 ± 7 vs. 142 ± 5 mmHg; p < 0.00002 and 76 ± 6 vs. 85 ± 6 mmHg; p < 0.00001). Central (aortic) systolic BP (119 ± 12 vs. 129 ± 13 mmHg; p < 0.01) and diastolic BP (79 ± 8 vs. 82 ± 10; p < 0.03) were also significantly decreased by losartan treatment. Prolonged use of losartan also led to a decrease in aortic stiffness, as determined by pulse wave velocity (PWV) (7.3 ± 1.8 vs. 7.8 ± 1.7 m/s; p < 0.04) and augmentation index (AI) (14 ± 18 vs. 19 ± 14%; p < 0.007). Treatment with losartan at a dose of 100 mg in mild hypertension decreases peripheral as well as central BP and aortic stiffness.

Keywords: Arterial hypertension; Blood pressure; Losartan

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J, Petrák O, Štrauch B, Vranková A, Zelinka T, Dvořáková J, Holaj R. The effects of losartan on central and peripheral blood pressure. Cor Vasa. 2010;52(3):183-186. doi: 10.33678/cor.2010.046.
Download citation

References

  1. Kaplan N. Clinical Hypertension. Philadelphia: Lippincott, Williams and Wilkins, 2006:518.
  2. Cheng JW. Aliskiren: renin inhibitor for hypertension management. Clin Ther 2008;30(1):31-46. Go to original source... Go to PubMed...
  3. Widimský J jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008;50:K3-K16.
  4. Weber MA. Angiotensin receptor blockers. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer. Philadelphia: Wolters Kluwer/Lippincott, Williams and Wilkins, 2008:461-464.
  5. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-15. Go to original source...
  6. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33: 1111-1117. Go to original source...
  7. Amar J, Ruidavets JB, Chamontin B, et al. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001;19: 381-387. Go to original source...
  8. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-670. Go to original source... Go to PubMed...
  9. O'Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis. Br J Clin Pharmacol 2001;51:507-522. Go to original source...
  10. Conlin PR, Spence JD, Wiliams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13(4 Pt 1): 418-426. Go to original source...
  11. Fabia MJ, Abdilla N, Oltra R, et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-1336. Go to original source... Go to PubMed...
  12. Krupička J, Ceypová K, Kristenová P, Hauser T. Bezpečnost dlouhodobého podávání losartanu v běžné klinické praxi: neintervenční studie NCT-CZ 14/04/LOZ. Vnitř Lék 2008;54:1031-1038. Go to PubMed...
  13. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21:821-848. Go to original source...
  14. Lindholm LH, Ibsen H, Dahlhöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010. Go to original source...
  15. Dahlhöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. Go to original source...
  16. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869. Go to original source...
  17. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875-886. Go to original source...
  18. Widimský J jr. Léčba hypertenze u metabolického syndromu. Vnitř Lék 2009;55:7-8, 631-635. Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.